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SObjective: The study objective was to evaluate histopathology of the esophagogastric anastomosis after esoph-
agectomy, determine time trends of histologic changes, and identify factors influencing those findings.
Methods: A total of 231 patients underwent 468 upper gastrointestinal endoscopies with anastomotic biopsy
a median of 3.5 years after esophagectomy. Mean age was 59  12 years, 74% (171) were male, and 96%
(222) were white. Seventy-eight percent (179) had esophagectomy for cancer, 13% (30) had chemoradiother-
apy, and 13% (30) had prior esophageal surgery. The anastomosis was 20  2.0 cm from the incisors. Anti-
reflux medications were used in 59% of patients (276/468) at esophagoscopy. Histopathology was graded as
normal (0), consistent with reflux (1), cardia mucosa (2), intestinal metaplasia (3), and dysplasia (4).
Repeated-measures nonlinear time-trend analysis and multivariable analyses were used.
Results:Grades 0 and 1 were constant, 5% and 92% at 10 years, respectively. Anti-reflux medication, induction
therapy, and higher anastomosis were predictive of less grade 1 histopathology. Grades 2 and 3 increased with
time: 12% and 33% at 5 years and 4% and 16% at 10 years, respectively. No variable was predictive of grade
2 or 3 (P>.15) except passage of time. No patient’s condition progressed to dysplasia or cancer.
Conclusions: The esophagogastric anastomosis is subject to gastroesophageal reflux. To minimize histopatho-
logic changes of reflux, the anastomosis should be constructed as high as possible (closer to incisors) and anti-
reflux medications prescribed. Surveillance endoscopy, if performed, will document a time-related progression
of reflux-related histopathologic changes. However, during surveillance, intestinal metaplasia is uncommon and
progression to cancer rare. (J Thorac Cardiovasc Surg 2011;141:875-80)Supplemental material is available online.
The normal esophagogastric junction is a complex, poorly
understood, dynamic zone of transition. Direct anastomosis
of the stomach to the esophagus at esophagectomy creates
an artificial environment, the study of which may increase
understanding of the esophagogastric junction and elucidate
the long-term impact of esophagectomy. Theoretically, at
this anastomosis, histopathologic changes of gastroesopha-
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The Journal of Thoracic and Cacolumnar metaplasia, dysplasia, and carcinoma may be
considerable. Since late 2005, esophagoscopy and biopsy
were added to routine annual surveillance after esophagec-
tomy for cancer and during postoperative evaluation after
esophagectomy for benign diseases. This afforded the op-
portunity to study histopathologic changes. The purposes
of this study were to evaluate histopathology of the esoph-
agogastric anastomosis after esophagectomy, determine
time trends of histopathologic changes, and identify factors
influencing those histologic findings.PATIENTS AND METHODS
From January 1, 1989, to January 1, 2009, 1758 patients underwent
esophagectomy at Cleveland Clinic; 1564 patients from one surgeon’s ex-
perience were potential candidates for endoscopic surveillance. From De-
cember 22, 2005, to September 4, 2009, 231 of these patients had 468 upper
gastrointestinal endoscopies with biopsy; 99% of the procedures (461)
were performed by the same surgical endoscopist. Patient characteristics
and indications for esophagectomy are listed in Table 1.
Esophagectomy
Esophagectomy (non–vagal-sparing) was accomplished transhiatally in
150 patients and with thoracotomy in 81 patients. Proximal gastrectomy in-
cluded thegastric cardia. All anastomoseswere constructed between the cer-
vical esophagus and the apex of the gastric fundus in an end-to-side fashion
via a left cervical incision.1 A pyloroplasty was constructed in all patients.
Surveillance Endoscopy
Esophagogastroduodenoscopy and biopsy were performed in the outpa-
tient area in all but 2 patients. Conscious sedation was used in all but 3rdiovascular Surgery c Volume 141, Number 4 875
Abbreviation and Acronym
GERD ¼ gastroesophageal reflux disease
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Spatients. Distance from incisors to the anastomosis was 20 2.0 cm (range,
16–30 cm; Figure E1). Gross endoscopic appearance of the anastomosis at
esophagoscopy was classified as normal (n ¼ 444, 95%), stricture (13,
2.8%), intestinal metaplasia (9, 1.9%), or nodule (2, 0.4%), but visual en-
doscopic grading of esophagitis was not done. Biopsies were performed us-
ing Radial Jaw 4 biopsy forceps (Boston Scientific, Natick, Mass). Any
gross abnormality was biopsied; 3 biopsies were taken from the esophageal
side, and 3 biopsies were taken from the gastric side of the anastomosis. At
the time of biopsy, 276 of 468 patients (59%) were receiving anti-reflux
therapy (primarily proton pump inhibitors and, rarely, H-2 blockers), pre-
scribed for symptoms of reflux.
The median interval between esophagectomy and first biopsy was 2.1
years (25th percentile, 1.2 years; 75th percentile, 4.8 years). Distribution
of data collection of graded biopsy outcomes over time is shown in
Figure E2.
Histopathology
Histopathologic changes were rated in a stepwise fashion of increasing
severity of changes: none (grade 0), changes consistent with reflux (grade
1: reactive, hyperplasia and regeneration, inflammatory), presence of
cardia mucosa (grade 2), presence of intestinal metaplasia (grade 3), and
dysplasia (grade 4).
Cancer recurrence at the anastomosis developed in only 1 patient during
the study (judged a cancer recurrence because of its early occurrence after
esophagectomy and lack of evidence of progression from intestinal meta-
plasia to cancer). The database was approved for use in research by the
institutional review board, with patient consent waived.
Statistical Analysis
To assess temporal trend of percentages of each biopsy grade across
time after esophagectomy, repeated measurements of biopsy grade were
analyzed using a nonlinear logistic mixed model,2 which resolved several
time phases of the temporal pattern of biopsy grade/temporal decomposi-
tion. Longitudinal logistic regression3 for repeated measurements4 (SAS
PROC NLMIXED; SAS Institute Inc, Cary, NC) was used to implement
the temporal decomposition model. Overall prevalence of each biopsy
grade was estimated by averaging the patient-specific profiles.
Patient-level variables—age, gender, prior hiatal hernia repair, prior
esophageal surgery, reason for esophagectomy (cancer vs benign), staged
approach (transhiatal vs thoracotomy), type of anastomosis (stapled vs
sewn), and induction therapy—and biopsy-level variables—location of
anastomosis and use of anti-reflux medication (as a surrogate for reflux
symptomology)—were considered in the multivariable analyses. The 2
biopsy-level variableswere treated as time-dependent covariables. For grade
1, however, the inability to determine side of origin of grade 2 to 4 changes
required analysis as a single finding (Table 2). To carry out this time-
dependent multivariable analysis, exogeneity was assumed, that is, the
time-varying covariablemeasurements at time twere conditionally indepen-
dent of all preceding response measurements (grades of biopsy outcomes).3
Presentation
Continuous variables are summarized by mean standard deviation, or
25th, 50th (median), and 75th percentiles for skewed data. Categoric data
are summarized by frequencies and percentages. All analyses were
performed using SAS statistical software (SAS v9.1; SAS, Inc). Uncer-
tainty is expressed by confidence limits equivalent to  1 standard error
(68%).876 The Journal of Thoracic and Cardiovascular SurgRESULTS
Histopathologic Changes
Of the 468 biopsies, 48 (10%) were classified as normal
(grade 0; Table 2). The majority (407 [87%]) showed
changes consistent with reflux (grade 1). These changes
were more pronounced on the esophageal side of the anas-
tomosis (75%) versus the stomach side (55%). Columnar
epithelium was found in 28% of biopsies, predominantly
gastric cardia (grade 2). Only 8.7% of patients were found
to have intestinal metaplasia. No biopsy showed dysplasia
(grade 4) or cancer.Time-Trend Analysis
Biopsies could show more than 1 grade of change. Thus,
each grade was analyzed separately.
Grade 0: Normal. Temporal trend yielded an almost con-
stant phase (Figure 1). Percentages of patients with grade
0 were relatively constant at 5% (Figure 1).
Grade 1: Reactive, hyperplasia and inflammatory, re-
generative. Temporal trend yielded an almost constant
phase. Percentages of patients with grade 1 were relatively
constant at 92% (Figure 2), but grade 1 features were some-
what more common on the esophageal side of the anastomo-
sis than the gastric side (Figure E3). Patients not receiving
anti-reflux medicine at the time of biopsy (Table 3,
P ¼ .01), those not receiving induction therapy (P ¼ .02),
and those with lower location of the anastomosis (farther
from the incisor teeth) (P ¼ .02) had increased likelihood
of grade 1 changes. No other variable was found to predict
a higher likelihood of grade 1 changes (P>.01).
Grade 2: Cardiamucosa. Temporal trend yielded an early
peaking and late slow rising phase (Figure 2). Percentages
of patients with grade 2 changes increased from 20% at 1
year to 24% by 2 years, decreased to approximately 12%
by year 5, and increased to 33% by year 10 (Figure 2).
No other variable predicted higher likelihood of having car-
dia mucosa (P>.1).
Grade 3: Intestinal metaplasia. Temporal trend yielded
a slightly increasing phase. Percentages of patients with in-
testinal metaplasia increased steadily from 0.68% at 1 year
to 16% at 10 years (Figure 2). No variable predicted a higher
likelihood of intestinal metaplasia at biopsy (P>.1).
Grade 4: Dysplasia. No patient was found to have
dysplasia.DISCUSSION
Principal Findings
Grade 1: Reactive, hyperplasia and inflammatory,
regenerative. It is inevitable that the esophagogastric
anastomosis will be subjected to gastroesophageal reflux.
Despite a relatively normal endoscopic appearance, histo-
pathologic changes associated with gastroesophageal reflux
predominated in our patients; these changes remainedery c April 2011
TABLE 2. Histopathologic findings
Variable
468 Biopsies
no. (%)
231 Patients
no. (%)
Esophageal side of anastomosis
Grade 0 77 (16) 16 (6.9)
Grade 1 350 (75) 195 (84)
Reactive 71 (15) 62 (27)
Hyperplasia and regeneration 110 (24) 87 (38)
Inflammatory 291 (62) 172 (74)
Stomach side of anastomosis
Grade 0 187 (40) 60 (26)
Grade 1 259 (55) 160 (69)
Reactive 26 (5.6) 22 (9.5)
Hyperplasia and regeneration 18 (3.8) 16 (6.9)
Inflammatory 257 (55) 160 (69)
Either side of anastomosis
Grade 0 48 (10) 6 (2.6)
Grade 1 407 (87) 137 (59)
Reactive 82 (18) 68 (29)
Hyperplasia and regeneration 116 (25) 92 (40)
Inflammatory 375 (80) 210 (91)
Grade 2 cardia mucosa 103 (22) 76 (33)
Grade 3 intestinal metaplasia 28 (6.0) 20 (8.7)
Grade 4 dysplasia 0 (0) 0 (0)
Other pathologic findings
Fungus 22 (4.7) 19 (8.2)
Eosinophils 22 (4.7) 19 (8.2)
TABLE 1. Patient characteristics and indications for esophagectomy
(n ¼ 231)
Variable No. (%)
Demographic
Male 171 (74)
White 224 (97)
Age (y), mean  SD 59  12 (25–84)
Prior esophageal surgery 30 (13)
Prior hiatal hernia repair 25 (11)
Reason for esophagectomy
Cancer 179 (78)
Induction therapy 30 (13)
Benign 52 (22)
Achalasia 30 (13)
GERD/failed anti-reflux surgery 19 (8.2)
Diverticulum 2 (0.9)
Benign tumor 1 (0.4)
Surgical approach
Thoracotomy 81 (35)
Transhiatal 150 (65)
GERD, Gastroesophageal reflux disease; SD, standard deviation.
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Sconstant at 92% from 1 year after esophagectomy. Three
other studies have evaluated these changes.5-7 The
reported non–time-related prevalence was 70%5 and
88%6 for intrathoracic anastomoses and 63% for cervical
anastomoses.6 After esophagectomy with cervical anasto-
mosis in patients with achalasia, da Rocha and colleagues7
reported esophagitis in 46% at 1 year, 72% at 5 years, and
70% at 10 years; the prevalence of gastritis was 20%, 31%,
and 40% at 1, 5, and 10 years, respectively.
Grade 2: Cardia mucosa. Native cardia mucosa is re-
sected at esophagectomy; therefore, this anastomotic find-
ing represents metaplasia of esophageal mucosa, gastric
mucosa, or both. Prevalence of columnar epithelium (cardia
mucosa or intestinal metaplasia) increased with time. This
change was present in one third of our patients at 10 years.
Seven studies examined these changes in a non–time-
related manner.5,6,8-12 Prevalence of cardia mucosa at
a median of 36 months ranged from 10%6 to 50%.11 In
one-time evaluations, the prevalence was 28%9 and 50%.10
Grade 3: Intestinal metaplasia. Intestinal metaplasia was
uncommon; its prevalence in our patients increased with
time to 16% at 10 years. Six studies have examined this
change.5,6,8-11 Prevalence ranged from 13.5% at a median
of 489 days8 to 27% at a median of 61 months.10
Two studies did not differentiate between grade 2 and
grade 3 changes and reported the finding of columnar
epithelium.7,12 Bax and colleagues12 reported columnar ep-
ithelium in 40% of patients at a mean of 59 months. In pa-
tients with achalasia, da Rocha and colleagues7 found
columnar epithelium in none at 1 year, 30% at 5 years,
and 58% at 10 years.
Grade 4: Dysplasia and cancer. Neither dysplasia nor
cancer was seen in our patients, mirroring the findings ofThe Journal of Thoracic and CaOberg and colleagues9 and Bax and colleagues.12 Lord
and colleagues11 reported 1 patient who progressed to
dysplasia and developed carcinoma 42 years after esopha-
gectomy. da Rocha and colleagues7 found 5 cancers (3 squa-
mous cell carcinomas and 2 adenocarcinomas) in patients
with achalasia. The 2 patients with adenocarcinomas at
13 and 19 years after esophagectomy progressed from intes-
tinal metaplasia.Predictors of Histopathologic Changes
Construction of the anastomosis as high as possible
(closer to the incisors), preoperative use of induction ther-
apy, and postoperative use of anti-reflux medication were
associated with fewer grade 1 changes in our patients. Pa-
tients receiving induction therapy are least likely to have
grade 1 changes, perhaps explained by cytotoxic effects
on the gastric mucosa. No predictors of histopathologic
reflux-related changes have been reported by others.
Time since esophagectomy was the only factor associ-
ated with developing columnar epithelium; this makes the
findings from this study particularly relevant to those whose
esophagectomy was for benign disease or early-stage grade
1 cancers. Time after esophagectomy was also the only re-
ported predictor of intestinal metaplasia in 2 studies.7,10
Magnitude of acid and bile exposure has been variably
reported to be associated with developing columnar
epithelium: an association with both,5 with acid but notrdiovascular Surgery c Volume 141, Number 4 877
FIGURE 1. Time trend of normal biopsies (grade 0) after esophagectomy.
Symbols represent data grouped within time frames without regard for
repeated assessment, simply to provide crude verification of model fit.
TABLE 3. Risk factors associated with higher likelihood of grade 1, 2,
and 3 changes
Risk factor Estimate ± SE P
Grade 1 changes
Overall
Female 0.63  0.56 .3
Prior hiatal hernia repair 0.0013  0.81 >.9
Prior surgery 1.6  1.1 .16
Older* 1.1  0.58 .06
No anti-reflux medication 1.1  0.42 .01
Anastomosis farther from incisorsy 5.6  2.4 .02
No induction therapy 1.3  0.54 .02
Stapled anastomosis (vs sewn) 0.16  0.72 .8
Malignant (vs benign) 0.21  0.81 .8
Surgical approach
Thoracotomy (vs transhiatal) 0.072  0.46 .9
Grade 2 changes
Overall
Female 0.31  0.48 .5
Younger* 0.41  0.52 .4
Prior surgery 0.32  0.64 .6
Anti-reflux medication 0.33  0.35 .3
Anastomosis farther from incisorsz 0.31  2.04 .9
Induction therapy 0.15  0.59 .8
Stapled (vs sewn) 0.47  0.98 .6
General Thoracic Surgery Rice et al
G
T
Sbile,9 and with neither.10 Columnar epithelium before
esophagectomy was associated with developing it postoper-
atively.9 Both intestinal metaplasia before esophagectomy
and lower level of anastomosis were associated with devel-
opment of intestinal metaplasia.6Surgical approach
Thoracotomy (vs transhiatal) 0.068  0.41 .9
Late phase
Malignant (vs benign) 0.65  0.41 .11
Prior hiatal hernia repair 1.2  0.80 .14
Grade 3 changes
Overall
Female 0.35  0.86 .7
Older* 1.2  0.88 .2
Anti-reflux medication 1.03  0.68 .13
Anastomosis farther from incisorsz 2.02  3.4 .6
Malignant (vs benign) 0.42  0.95 .7
Stapled (vs sewn) 0.16  1.003 .9
SE, Standard error. *(Age/60)2, squared transformation. y(20/location of anastomo-Strengths and Limitations
This is a single-institution prospective study based on
histopathologic changes and not visual assessment of the
anastomosis. However, sampling error during biopsy may
underestimate the prevalence of these histopathologic
changes. All anastomoses were performed through a cervi-
cal incision. Although the majority werewithin 20 cm of the
incisors, there was a range, allowing this factor to be as-
sessed. Anti-reflux medications were not randomly pre-
scribed but used for symptom control, which may affect
the association with histopathologic reflux changes. FailureFIGURE 2. Time trend of histopathologic changes at esophagogastric
anastomoses. Combined esophageal and gastric findings. Grade
1 ¼ changes consistent with reflux. Grade 2 ¼ presence of cardia mucosa.
Grade 3 ¼ presence of intestinal metaplasia. Depiction is as in Figure 1.
sis), inverse transformation. zLog(location of anastomosis), logarithmic transforma-
tion.
878 The Journal of Thoracic and Cardiovascular Surgto identify associations with columnar epithelium may be
related to the size of the study population, large by current
studies, but possibly too small to detect associations.
CONCLUSIONS
The esophagogastric anastomosis is inevitably exposed
to reflux. Careful surgical technique, including a high
stapled anastomosis, and postoperative management, in-
cluding medical treatment of GERD, may minimize histo-
pathologic reflux changes. With time, columnar mucosa
will develop in a minority of patients, and intestinal meta-
plasia will develop in even fewer patients. Progression of
intestinal metaplasia to dysplasia or cancer seems rare.
Therefore, annual surveillance endoscopy is of limitedery c April 2011
Rice et al General Thoracic Surgeryvalue, particularly in asymptomatic patients (ie, those not
taking anti-reflux medication). Rather, endoscopy should
be directed toward detection of cancer recurrence and diag-
nosis of symptoms.G
T
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Discussion
Dr Farzaneh Banki (Houston, Tex). I thank Drs Milliken and
Bremner for the opportunity to discuss this article and congratulate
Dr Rice and colleagues on providing the largest series with long-term
follow-up that elucidates the fate of gastroesophageal anastomosis
and mucosal changes in esophageal remnant after esophagectomy.
This study has multiple clinical implications, including the need
for surveillance and use of proton-pump inhibitor after esophagec-
tomy, and once again proves that cardiac mucosa is an acquired
metaplastic epithelium that arises from squamous mucosa in re-
sponse to gastric acid. I have 3 questions.
In your study, the curve for development of cardiac mucosa is
biphasic, so there is an early and a late development of cardiac mu-
cosa, but the development of intestinal metaplasia is linear and in-
creases with time. Although one can explain the early development
of cardiac mucosa by acute exposure of the esophageal remnant to
acid and bile, and the late development by chronic exposure and by
the fact that despite vagotomy the stomach regains its capacity to
produce acid with time, how do you explain the decline between
2.5 and 4.5 years in development of cardiac mucosa in your study?The Journal of Thoracic and CaDr Rice. I think it is explained by sampling error. If you don’t
biopsy the columnar mucosa, you are not going to find it. We tried
to do another analysis on reaching the greatest change, but that be-
came very confusing to present.
Dr Banki. Prior studies with a small number of patients have
shown that presence of intestinal metaplasia in the esophagus be-
fore esophagectomy is an important predictive factor for develop-
ment of intestinal metaplasia in esophageal remnant after
esophagectomy. Have you considered that as a factor in your mul-
tivariate analysis?
DrRice. That variable was not considered. We hope that benign
versus malignant indication would be a surrogate. I would remind
you that the studies on intestinal metaplasia, and it is a variable fac-
tor (yes in some studies and no in others), were done mostly in pa-
tients with low intrathoracic anastomosis, and we have no idea
about the surgical margin. Indeed, if you don’t take out the Bar-
rett’s and you do your first biopsy, you are going to find Barrett’s
because your operation was incomplete—another reason to go
high in the neck. But you are absolutely right, we should probably
add to our analysis the presence of Barrett’s mucosa before the
esophagectomy.
Dr Banki. Have you changed your yearly surveillance protocol
for endoscopy and routine biopsies and the use of proton-pump
inhibitors in your patients after esophagectomy as a result of this
article?
Dr Rice. I still use proton-pump inhibitors for symptoms, but I
have a low tolerance to use them. Of course we are going to do our
surveillance for cancer recurrence, but I think surveillance for can-
cer progression is probably not wise. Maybe if you are going to do
it every 5 years, it may be a good way to check for progression of
Barrett’s at the anastomosis.
Dr Ross Bremner (Phoenix, Ariz). Tom, have you considered
doing an anti-reflux procedure? Glyn Jamieson and his group in
Australia just published some compelling data on a prospective
study they did with a high intrathoracic anti-reflux procedure
that showed no difference in dysphagia but a remarkable differ-
ence in reflux. Is that something you would consider doing?
DrRice.Doyoumean a fundoplication about a low anastomosis?
Dr Bremner. Actually just do an anti-reflux high up in the
chest.
DrRice. I try to use full gastric tube, full gastric remnant, when-
ever I can, but usually there is not enough stomach in the neck to do
that anti-reflux procedure.
Dr Steve Demeester (Los Angeles, Calif). Tom, those are nice
data, important data. What was the longest length of columnar mu-
cosa that you saw develop over time in these patients?
Dr Rice.We did not rely on the measurement of columnar mu-
cosa. Most of the columnar mucosa we found was on histopatho-
logic biopsy, but we did see a few cases endoscopically of
approximately 1 cm.
Dr Demeester. So most of the time the anastomosis appeared
relatively normal.
Dr Rice. Yes, to my eye it appeared relatively normal and the
reflux changes were histopathologic, and surprisingly, a number
were ulcerative when things looked reasonably okay.
Dr Demeester. Good, and then just a follow-up question on
that. In light of this, the Cleveland Clinic, in particular John (Gold-
blum), has been a big proponent that all cardiac mucosa intestinalrdiovascular Surgery c Volume 141, Number 4 879
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Smetaplasia at the gastroesophageal junction in its normal location
is a Helicobacter pylori–related phenomenon. Has this altered his
thinking at all seeing these data?
Dr Demeester.You will have to talk to John, but we discuss this
frequently. His belief is that the cardia mucosa in its normal posi-
tion at the esophagogastric junction, which of course we excise880 The Journal of Thoracic and Cardiovascular Surgduring this operation, is normal mucosa, and when we find it any-
where else it is metaplastic. Certainly with some of the findings we
observed, it is hard to tell where the columnar mucosa was at that
anastomosis, but one could believe that some of it was on the gas-
tric side of the anastomosis. So we are learning about the esopha-
gogastric junction and the esophagogastric anastomosis.ery c April 2011
FIGURE E2. Number of patients with biopsies available at and beyond
various time points, and number of biopsies available for analysis (black
bars ¼ biopsies; grey bars ¼ patients).
FIGURE E1. Cumulative distribution of distance from incisors to anasto-
mosis.
FIGURE E3. Time trend of grade 1 changes at esophageal and gastric
sites. Symbols represent data grouped within time frames without regard
for repeated assessment, simply to provide crude verification of model fit.
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